Brown, NF;
Carter, T;
Kitchen, N;
Mulholland, P;
(2017)
Dabrafenib and trametinib in BRAFV600E mutated glioma.
CNS Oncology
, 6
(4)
10.2217/cns-2017-0006.
Preview |
Text
Dabrafenib and trametinib in BRAFV600E mutated glioma.pdf - Published Version Download (943kB) | Preview |
Abstract
BRAFV600E mutations have been identified in a number of glioma subtypes, most frequently in pleomorphic xanthoastrocytoma, ganglioglioma, pilocytic astrocytoma, and epithelioid glioblastoma. Although the development of BRAF inhibitors has dramatically improved the clinical outcome for patients with BRAFV600E mutant tumors, resistance develops in a majority of patients due to reactivation of the MAPK pathway. Addition of MEK inhibition to BRAF inhibition improves survival. Here we report successful treatment of two patients with BRAFV600E mutant pleomorphic xanthoastrocytoma using the BRAF inhibitor dabrafenib in combination with the MEK inhibitor trametinib.
Type: | Article |
---|---|
Title: | Dabrafenib and trametinib in BRAFV600E mutated glioma. |
Open access status: | An open access version is available from UCL Discovery |
DOI: | 10.2217/cns-2017-0006 |
Publisher version: | https://doi.org/10.2217/cns-2017-0006 |
Language: | English |
Additional information: | This version is the version of record. For information on re-use, please refer to the publisher’s terms and conditions. |
Keywords: | anaplastic, BRAFV600E mutation, dabrafenib, glioma, pleomorphic xanthoastrocytoma, trametinib |
UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute |
URI: | https://discovery.ucl.ac.uk/id/eprint/10076955 |
Archive Staff Only
View Item |